At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 150 enrolled
Drug / intervention
Tezepelumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicentre, Randomized, Double-Blind, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma (SOURCE)
In Brief
A Phase 3 clinical trial evaluating Tezepelumab and Placebo for Asthma. Completed, enrolled 150 participants across 60 sites in 7 countries.
Detailed Summary
Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults with Oral Corticosteroid Dependent Asthma
Study Details
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedJan 2018
Enrollment StartMar 2018
Primary CompletionSep 2020
TodayJul 2026
First PostedJan 23, 2018
Enrollment StartMar 5, 2018
Primary CompletionSep 25, 2020
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 8.4 years ago
Interventions
Tezepelumabbiological
Tezepelumab subcutaneous injection
Placeboother
Placebo subcutaneous injection